Cover Image
市場調查報告書

疫苗的銷售額分析 (2016-2026年):兒童用、成人用、老年人用疫苗的市場趨勢、R&D、收益預測

Vaccine Sales Analysis 2016-2026: Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases

出版商 Visiongain Ltd 商品編碼 357614
出版日期 內容資訊 英文 186 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗的銷售額分析 (2016-2026年):兒童用、成人用、老年人用疫苗的市場趨勢、R&D、收益預測 Vaccine Sales Analysis 2016-2026: Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases
出版日期: 2016年03月23日 內容資訊: 英文 186 Pages
簡介

本報告提供全球疫苗市場相關調查,人類疫苗概要、目的、技術、對象者區分,主要企業相關團體,市場規模 (收益規模) 的變化與預測,各主要疫苗、接種對象者及目的、主要已開發國家/新興國家的詳細分析,主要製造商的配合措施,研發產品線趨勢,定性分析等彙整資料。

第1章 調查概要

第2章 全球人類疫苗市場:簡介

  • 人類疫苗:全球性疾病預防的追求
  • 社會負擔和經濟負擔
  • 疫苗技術
    • 不活化疫苗
    • 減毒活病毒疫苗
    • 共軛疫苗
    • 重組載體疫苗
  • 人類疫苗市場相關企業、團體
    • 政府、國際組織
      • WHO
      • 政府的影響
    • 主要製造商
      • Merck & Co.
      • Sanofi
      • GlaxoSmithKline
      • Pfizer
  • 疫苗區分
    • 兒童用疫苗
    • 成人用疫苗
    • 老年人用疫苗
    • 出國者用疫苗
    • 治療疫苗

第3章 全球疫苗市場預測

  • 全球市場現況
  • 全球市場的預測
  • 產業趨勢、預測

第4章 全球疫苗市場預測:各種類

  • 兒童用疫苗
    • 市場預測
    • 市場趨勢
  • 成人用疫苗
    • 市場預測
    • 市場趨勢
  • 老年人用疫苗
    • 市場預測
    • 市場趨勢
  • 出國者用疫苗
    • 市場預測
    • 市場趨勢
  • 治療疫苗
    • 市場趨勢

第5章 主要疫苗的收益預測

  • Prevnar:肺炎球菌性肺炎
  • Gardasil:HPV
  • Fluzone:流感
  • Pentacel:DtaP、小兒麻庳、HiB
  • ProQuad / M-M-R II / Varivax:水痘、麻疹、腮腺炎感冒、德國麻疹
  • Infanrix/Pediarix:白喉、破傷風、無細胞百日咳
  • Zostavax:帶狀皰疹
  • RotaTeq:輪狀病毒
  • GSK Hepatitis Franchise:A型、B型肝炎
  • Menactra:腦膜炎

第6章 主要先進國家市場的預測

  • 美國
    • 市場成果
    • 市場預測
  • 日本
    • 市場成果
    • 市場預測
    • 疫苗差距的應對
  • 歐盟5國
    • 市場成果
    • 市場預測
  • 英國
    • 市場成果
    • 市場預測
  • 法國
    • 市場成果
    • 市場預測
    • 法國的醫療制度:疫苗接種政策
  • 德國
    • 市場成果
    • 市場預測
  • 義大利
    • 市場成果
    • 市場預測
    • 公共醫療方面課題
  • 西班牙
    • 市場成果
    • 市場預測
    • 各地區統一控制:經濟課題

第7章 主要新興國家市場預測

  • 中國
    • 市場成果
    • 市場預測
    • 國內疫苗產業的建立
  • 印度
    • 市場成果
    • 市場預測
    • 疫苗市場發展的範圍
  • 巴西
    • 市場成果
    • 市場預測
    • 茲卡病毒的流行
  • 俄羅斯
    • 市場成果
    • 市場預測
    • 聯邦國之力

第8章 人體疫苗的主要製造商

  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • 其他

第9章 R&D現況

  • 預防疫苗的研發產品線
    • 兒童用
    • 成人用
    • 老年人用
    • 出國者用
  • 治療疫苗的研發產品線

第10章 定性分析

  • SWOT分析
  • STEP分析

第11章 總論

圖表

目錄
Product Code: PHA0100

Vaccines - Your 2016 Guide to Developments, Opportunities and Revenues

What does the future hold for vaccine sales? Visiongain's updated report shows you forecasted sales at overall world market, submarket, product and national level to 2026.

With that study you discover vaccine trends, R&D and revenue prospects for human healthcare. That way you can benefit your research, analysis, decisions and authority. For those technologies, assess sales potentials and opportunities.

Vaccines still hold great technological, medical and commercial potential. See why and what is possible. Read on, then, to explore that industry and see a revenue prediction.

Forecasts from 2016 to 2026 and other analyses showing you vaccine market potentials

Besides revenue forecasting to 2026, our new study gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).

Our report gives you 52 tables and 56 charts. Gain analysis found nowhere else. Discover what the future holds for companies and the vaccines market.

Gains through exploring the vaccines industry - ways to benefit your plans and decisions

Leaders hold the latest knowledge - research and analysis. So explore, in our report, the development, production and sales of vaccines. There, from 2016, you see where needs and money exist for those preventative medicines. Discover what is possible.

Our study's purpose is to help you avoid struggles to gain business data on vaccines. See how our predictions and discussions could benefit your reputation for commercial insight.

Discover, then, how you and your organisation can gain. The following sections show how our new investigation benefits your plans, decisions and presentations.

Revenues for the world vaccines market and submarkets - what is possible?

What is that industry's potential? What are the secrets of its progress? Discover in our report overall world revenue forecasting to 2026. Also find individual predictions for four world level submarkets:

  • Paediatric vaccines
  • Adult vaccines
  • Elderly vaccines
  • Travel vaccines.

How will sales rise? And which product classes can generate most revenue? In our work you assess prospects for commercial expansion. You see which vaccine types hold greatest potential for sales growth and high revenues.

Benefit your knowledge and authority. You also discover sales potentials of vaccines by brand.

Forecasts and discussions for leading marketed products

How will leading brands perform from 2016 at world level? Our work shows you 10 individual revenue forecasts to 2026 for leading vaccines:

  • Prevnar
  • Gardasil
  • Fluzone
  • Pentacel
  • ProQuad/M-M-R- II/Varivax.

You also see revenue predictions to 2026 for these products:

  • Infanrix/Pediarix
  • Zostavax
  • RotaTeq
  • GSK hepatitis franchise
  • Menactra.

Avoid falling behind in information to help you stay competitive. Instead our work lets you assess potentials, seeing activities, results and outlooks. You discover what is happening, exploring trends, competition and sales prospects.

Our study also divides its overall world vaccines forecast into geographical regions.

Healthcare in national markets - what outlooks for sales of those medicines?

Progress worldwide in vaccines and healthcare from 2016 will increase vaccination. With our investigation you hear about the best revenue prospects for those medicines, assessing national prospects.

Our analysis shows you individual revenue forecasts to 2026 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (EU5 countries)
  • Brazil, Russia, India and China (BRIC group).

There you assess developed and developing countries for revenues and future sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Future vaccines - assess emerging technologies, exploring research and development

Our study also shows you the most promising vaccines in development. There explore product candidates in these six classes:

  • Prophylactic vaccines
  • Products for children
  • Agents for protecting adults
  • Treatments for older people
  • Travel vaccination
  • Therapeutic vaccines.

R&D for vaccines holds great potential to benefit companies, healthcare providers and patients. See what technological, clinical and commercial opportunities exist, helping you stay ahead.

Our study explains progress in human prophylaxis, discussing issues to help your work.

Events affecting developers, producers and sellers of vaccines

Assess forces affecting that industry and market from 2016, including these issues:

  • Importance of vaccine production to the pharmaceutical industry
  • Immunisation needs and progress in developed and developing countries
  • Rising vaccination needs in emerging countries and under-developed regions, including fighting influenza pandemics and the Zika virus
  • Developments for combating HIV, cancer, addictions and other emerging uses
  • Delivery systems and other innovations improving vaccines' performance.

With our survey you explore political, economic, social and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market, seeing what the future holds.

Leading vaccine producers and that industry's overall 2020 market value

What happens next? Our report predicts the overall world market for vaccines will reach $49.8bn worldwide in 2020, with strong revenue expansion from 2016 to 2026.

See how high its revenues can go. Discover in our work what is possible for vaccine production and sales, and see which companies hold greatest potential.

In particular our work assesses these organisations:

  • GlaxoSmithKline
  • Merck & Co.
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca.

From 2016 to 2026 vaccines will benefit patients, payers and companies, rising in prominence. Our analysis predicts advances there. Stay ahead by getting that study.

Ways Vaccine Sales 2016-2026 benefits your work - gain data you find nowhere else

In particular, our new investigation gives you these analyses to help your research, plans, decisions and proposals:

  • Revenues to 2026 for vaccines at world level and for 4 main submarkets - assess prospects for investments, marketing and sales
  • Predictions for 10 products to 2026 - discover revenue potentials of leading vaccines, seeing how they can compete and succeed
  • Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
  • Prospects for established competitors and rising companies - explore products, R&D and outlooks for success.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.

With our study, by visiongain's UK-based analysts, you avoid missing out on data to help you stay ahead. See what the future holds for vaccine developers, producers and sellers.

Trying our new report now lets you discover vaccine trends, opportunities and forecasts

Our investigation is for everyone analysing preventive medicines and related biotechnology. There you discover data and forecasts for human vaccines. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the World Vaccines Market
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analytical Study
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to the World Human Vaccines Market

  • 2.1. Human Vaccines - Aiming for Global Disease Prevention
  • 2.2. What is the Social and Economic Burden?
  • 2.3. Vaccine Technology
    • 2.3.1. Inactivated Vaccines
    • 2.3.2. Live Attenuated Vaccines
    • 2.3.3. Conjugate Vaccines
    • 2.3.4. Recombinant Vector Vaccines
  • 2.4. Key Influencers of the Human Vaccine Market
    • 2.4.1. Governments and International Organizations
      • 2.4.1.1. The World Health Organisation (WHO)
      • 2.4.1.2. The Governmental Influence
    • 2.4.2. Leading Manufacturers
      • 2.4.2.1. Merck & Co.
      • 2.4.2.2. Sanofi
      • 2.4.2.3. GlaxoSmithKline
      • 2.4.2.4. Pfizer
  • 2.5. Human World Vaccines - Market Segmentation
    • 2.5.1. Paediatric Vaccines
    • 2.5.2. Adult Vaccines
    • 2.5.3. Elderly Vaccines
    • 2.5.4. Travel Vaccines
    • 2.5.5. Therapeutic Vaccines

3. World Vaccine Market Outlook, 2016-2026

  • 3.1. World Vaccine Market, 2015
    • 3.1.1. Paediatric Vaccines Maintains Constant Demand
    • 3.1.2. Ageing Population Requires More Care
    • 3.1.3. Emerging Markets Demand Better Immunity
  • 3.2. The World Human Vaccines Forecast, 2016-2026
  • 3.3. The World Vaccine Market: Industry Trends, 2016-2026
    • 3.3.1. Undulating Demand
    • 3.3.2. Supply Restraints
    • 3.3.3. Funding Trends
    • 3.3.4. Protecting the Workforce of an Economy

4. World Vaccine Submarkets: Prospects, 2016-2026

  • 4.1. Paediatric Vaccines
    • 4.1.1. Paediatric Vaccine Forecast, 2016-2026
    • 4.1.2. Paediatric Vaccine Trends
      • 4.1.2.1. Innovative Delivery
      • 4.1.2.2. Fear Factor
      • 4.1.2.3. Novel Vectors
  • 4.2. Adult Vaccines
    • 4.2.1. Adult Vaccine Forecast, 2016-2026
    • 4.2.2. Adult Vaccine Trends
      • 4.2.2.1. Fighting the Flu
      • 4.2.2.2. HPV
      • 4.2.2.3. Repeat Doses for Continued Protection
  • 4.3. Elderly Vaccines
    • 4.3.1. Elderly Vaccine Forecast, 2016-2026
    • 4.3.2. Elderly Vaccine Trends
      • 4.3.2.1. With Age Comes Greater Risk
      • 4.3.2.2. Ageing Population across the Globe
  • 4.4. Travel Vaccines
    • 4.4.1. Travel Vaccines Forecast, 2016-2026
    • 4.4.2. Travel Vaccine Trends
      • 4.4.2.1. Zika Virus Outbreak
      • 4.4.2.2. Globalization Carries Diseases
  • 4.5. Therapeutic Vaccines
    • 4.5.1. Therapeutic Vaccine Trends

5. Leading Vaccines: Revenue Forecasts, 2016-2026

  • 5.1. Prevnar - Pneumococcal Pneumonia
  • 5.2. Gardasil - HPV
  • 5.3. Fluzone - Influenza
  • 5.4. Pentacel - DtaP, Polio, HiB
  • 5.5. ProQuad / M-M-R II / Varivax - Varicella/Chickenpox, Measles, Mumps, Rubella.
  • 5.6. Infanrix/Pediarix - Diptheria, Tetanus and Acellular Pertussis
  • 5.7. Zostavax - Herpes
  • 5.8. RotaTeq - Rotavirus
  • 5.9. GSK Hepatitis Franchise - Hepatitis A & B
  • 5.10. Menactra - Meningococcal

6. Leading Developed National Vaccines Markets, 2016-2026

  • 6.1. The United States Vaccines Markets, 2016-2026
    • 6.1.1. The US Vaccine Market, 2016
    • 6.1.2. The US Vaccine Market Forecast, 2016-2026
  • 6.2. Japanese Vaccines Market, 2016-2026
    • 6.2.1. The Japanese Vaccine Market, 2016
    • 6.2.2. The Japanese Vaccine Market Forecast, 2016-2026
    • 6.2.3. Addressing the Alleged Vaccine Gap
  • 6.3. EU5. Vaccine Market, 2016-2026
    • 6.3.1. The EU5 Vaccine Market, 2016
    • 6.3.2. The EU5 Vaccine Market Forecast, 2016-2026
  • 6.4. United Kingdom Vaccine Market, 2016-2026
    • 6.4.1. The UK Vaccine Market, 2016
    • 6.4.2. The UK Vaccine Market Forecast, 2016-2026
  • 6.5. France: Vaccine Market, 2016-2026
    • 6.5.1. The French Vaccine Market, 2016
    • 6.5.2. The French Vaccine Market Forecast, 2016-2026
    • 6.5.3. French Healthcare System - Immunization Policy
  • 6.6. Germany: Vaccine Market, 2016-2026
    • 6.6.1. The German Vaccine Market, 2016
    • 6.6.2. The German Vaccine Market Forecast, 2016-2026
  • 6.7. Italy: Vaccine Market, 2016-2026
    • 6.7.1. The Italian Vaccine Market, 2016
    • 6.7.2. The Italian Vaccine Market Forecast, 2016-2026
    • 6.7.3. Challenges in Public Healthcare
  • 6.8. Spain: Vaccine Market 2016-2026
    • 6.8.1. The Spanish Vaccine Market, 2016
    • 6.8.2. The Spanish Vaccine Market Forecast, 2016-2026
    • 6.8.3. District Rules - Economic Challenges

7. Leading Emerging National Markets, 2016-2026

  • 7.1. China: Vaccine Market, 2016-2026
    • 7.1.1. The Chinese Vaccine Market, 2016
    • 7.1.2. The Chinese Vaccine Market Forecast, 2016-2026
    • 7.1.3. Setting-Up Domestic Vaccine Industries
  • 7.2. India: Vaccine Market, 2016-2026
    • 7.2.1. The Indian Vaccine Market, 2016
    • 7.2.2. The Indian Vaccine Market Forecast, 2016-2026
    • 7.2.3. The Extent to which the Vaccine Market Can Flourish?
  • 7.3. Brazil: Vaccine Market, 2016-2026
    • 7.3.1. The Brazilian Vaccine Market, 2016
    • 7.3.2. The Brazilian Vaccine Market Forecast, 2016-2026
    • 7.3.3. Zika Outbreak
  • 7.4. Russia: Vaccine Market, 2016-2026
    • 7.4.1. The Russian Vaccine Market, 2016
    • 7.4.2. The Russian Vaccine Market Forecast, 2016-2026
    • 7.4.3. Power of the State

8. Leading Manufacturers of Vaccines for Human Use

  • 8.1. GlaxoSmithKline (GSK)
    • 8.1.1. GSK Vaccine Performance
    • 8.1.2. GSK Developments
      • 8.1.2.1. Mergers and Acquisitions
      • 8.1.2.2. GSK Vaccine Pipeline
  • 8.2. Merck & Co.
    • 8.2.1. Merck Vaccine Performance
    • 8.2.2. Merck Developments
      • 8.2.2.1. Merck Market Movements
      • 8.2.2.2. Collaborations
      • 8.2.2.3. Merck Pipeline
  • 8.3. Sanofi
    • 8.3.1. Sanofi Vaccine Performance
    • 8.3.2. Sanofi Developments
      • 8.3.2.1. Mergers & Acquisitions
      • 8.3.2.2. Sanofi Vaccine Pipeline
  • 8.4. Pfizer
    • 8.4.1. Pfizer Vaccine Performance
    • 8.4.2. Pfizer Developments
      • 8.4.2.1. Pfizer Mergers & Acquisitions
      • 8.4.2.2. Pfizer Pipeline
  • 8.5. Johnson & Johnson
  • 8.6. AstraZeneca
  • 8.7. Other Companies Serving the Vaccines Market

9. Research and Development, 2016

  • 9.1. Prophylactic Vaccines R&D Pipeline
    • 9.1.1. Paediatric Vaccines R&D Pipeline
    • 9.1.2. Adult Vaccines R&D Pipeline
    • 9.1.3. Elderly Vaccines R&D Pipeline
    • 9.1.4. Travel Vaccines R&D Pipeline
  • 9.2. Therapeutic Vaccines R&D Pipeline

10. Qualitative Analysis of the World Vaccines Market, 2016-2026

  • 10.1. SWOT Analysis of the World Human Vaccines Market, 2016
    • 10.1.1. Strengths
      • 10.1.1.1. Ageing Population
      • 10.1.1.2. Prevention is Better than Cure
      • 10.1.1.3. Demand from Emerging Markets Continue
      • 10.1.1.4. Promising R&D Pipeline
      • 10.1.1.5. Increasing Awareness
    • 10.1.2. Weaknesses
      • 10.1.2.1. High Manufacturing Costs
      • 10.1.2.2. Time Constraints
      • 10.1.2.3. Barriers to Market Entry
    • 10.1.3. Opportunities
      • 10.1.3.1. Constant Improvements in Vaccine Technology and Delivery Methods
      • 10.1.3.2. Shifting Focus on Adults Vaccines
    • 10.1.4. Threats
      • 10.1.4.1. Oligarchic Presence of Pharmaceutical Giants
      • 10.1.4.2. Productivity Gap
  • 10.2. STEP Analysis of the World Human Vaccines Industry and Market, 2016-2026
    • 10.2.1. Social Factors
      • 10.2.1.1. Maintaining a Healthier Workforce
      • 10.2.1.2. Public Hesitation - Fear of Unwanted Side-Effects
    • 10.2.2. Technological Forces
      • 10.2.2.1. Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
    • 10.2.3. Economic Factors
      • 10.2.3.1. High Costs of Production
      • 10.2.3.2. Soaring Vaccines Demand from Developing Countries
    • 10.2.4. Political Factors
      • 10.2.4.1. Governments Play Crucial Roles in Vaccination

11. Conclusions

  • 11.1. Segment Market Share Shift
  • 11.2. Elderly People Become the New Target Market
  • 11.3. Endemic Infections Drive Travel Vaccines Growth
  • 11.4. Emerging Markets: High Demand for Vaccines
  • 11.5. Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
  • 11.6. Strong and Diverse Research and Development
  • 11.7. Concluding Remarks

List of Tables

  • Table 1.1: Selected National Vaccines Markets: Revenues ($bn) and Market Shares (%) by Leading Country, 2014, 2020 and 2026 (Sample)
  • Table 3.1: The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2015-2026
  • Table 4.1: World Vaccines Submarkets: Revenue Forecasts ($bn), 2015-2026
  • Table 4.2: World Vaccines Submarkets: Market Shares (%), 2015-2026
  • Table 4.3: World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.4: World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.5: World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.6: World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.1: Prevnar Revenue ($bn), 2011-2014
  • Table 5.2: Prevnar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.3: Gardasil Revenue ($bn), 2011-2014
  • Table 5.4: Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.5: Fluzone/Vaxigrip: Revenue ($bn), 2012-2014
  • Table 5.6: Fluzone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.7: Pentacel Revenue ($bn), 2012-2014
  • Table 5.8: Pentacel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.9: ProQuad / M-M-R II / Varivax Revenue ($bn), 2011-2014
  • Table 5.10: ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.11: Infanrix/Pediarix Revenue ($bn), 2012-2014
  • Table 5.12: Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.13: Zostavax Revenue ($bn), 2011-2014
  • Table 5.14: Zostavax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.15: RotaTeq Revenue ($bn), 2011-2014
  • Table 5.16: RotaTeq Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.17: GSK Hepatitis Franchise Revenue ($bn), 2012-2014
  • Table 5.18: GSK Hepatitis Franchise Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.19: Menactra Revenue ($bn), 2012-2014
  • Table 5.20: Menactra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.1: Leading National Market Revenue Forecasts ($bn), 2015, 2020, 2026
  • Table 6.2: Leading Developed National Market Revenue Forecasts ($bn), 2015, 2020, 2026
  • Table 6.3: Leading Developed National Market Shares (%), 2015, 2020, 2026
  • Table 6.4: The US Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.5: The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.6: EU5 Vaccines World Market Shares (%), 2015, 2020, 2026
  • Table 6.7: EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.8: The UK Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.9: The French Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.10: The German Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.11: The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 6.12: The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.1: Leading Emerging National Market Revenue Forecasts ($bn), 2015, 2020, 2026
  • Table 7.2: Leading Emerging National Market Shares (%), 2015, 2020, 2026
  • Table 7.3: The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.4: The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.5: The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.6: The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 8.1: GSK Geographic Revenue ($bn), 2014
  • Table 9.1: Prophylactic Vaccines in Development, 2016
  • Table 9.2: Paediatric Vaccines in Development, 2016
  • Table 9.3: Adult Vaccines in Development, 2016
  • Table 9.4: Elderly Vaccines in Development, 2016
  • Table 9.5: Travel Vaccines in Development, 2016
  • Table 9.6: Therapeutic Vaccines in Development, 2016

List of Figures

  • Figure 1.1: World Vaccines Market Segmentation, 2016
  • Figure 3.1: Vaccines Market Share within Global Pharmaceutical Market (%), 2016
  • Figure 3.2: World Vaccines Leading National Market Shares (%), 2015
  • Figure 3.3: World Vaccines Leading National Market Shares (%), 2020
  • Figure 3.4: World Vaccines Leading National Market Shares (%), 2026
  • Figure 3.5: World Vaccines Market: Drivers and Restraints, 2016-2026
  • Figure 4.1: World Prophylactic Vaccines Submarket (%) Segmentation, 2015
  • Figure 4.2: World Paediatric Vaccines Market Share (%), 2014
  • Figure 4.3: World Paediatric Vaccines Market Share (%), 2020
  • Figure 4.4: World Paediatric Vaccines Market Share (%), 2026
  • Figure 4.5: World Paediatric Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 4.6: World Adult Vaccines Market Share (%), 2014
  • Figure 4.7: World Adult Vaccines Market Share (%), 2020
  • Figure 4.8: World Adult Vaccines Market Share (%), 2026
  • Figure 4.9: World Adult Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 4.10: World Elderly Vaccines Market Share (%), 2014
  • Figure 4.11: World Elderly Vaccines Market Share (%), 2020
  • Figure 4.12: World Elderly Vaccines Market Share (%), 2026
  • Figure 4.13: World Elderly Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 4.14: World Travel Vaccines Market Share (%), 2014
  • Figure 4.15: World Travel Vaccines Market Share (%), 2020
  • Figure 4.16: World Travel Vaccines Market Share (%), 2026
  • Figure 4.17: World Travel Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 5.1: Prevnar Revenue Forecast ($bn), 2015-2026
  • Figure 5.2: Gardasil Revenue Forecast ($bn), 2015-2026
  • Figure 5.3: Fluzone Revenue Forecast ($bn), 2015-2026
  • Figure 5.4: Pentacel Revenue Forecast ($bn), 2015-2026
  • Figure 5.5: ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), 2015-2026
  • Figure 5.6: Infanrix/Pediarix Revenue Forecast ($bn), 2015-2026
  • Figure 5.7: Zostavax Revenue Forecast ($bn), 2015-2026
  • Figure 5.8: RotaTeq Revenue Forecast ($bn), 2015-2026
  • Figure 5.9: GSK Hepatitis Franchise Revenue Forecast ($bn), 2015-2026
  • Figure 5.10: Menactra Revenue Forecast ($bn), 2015-2026
  • Figure 6.1: The US Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 6.2: The Japanese Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 6.3: EU5 Vaccines Market Share (%), 2015
  • Figure 6.4: EU5 Vaccines Market Share (%), 2020
  • Figure 6.5: EU5 Vaccines Market Share (%), 2026
  • Figure 6.6: The UK Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 6.7: The French Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 6.8: The German Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 6.9: The Italian Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 6.10: The Spanish Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 7.1: BRIC Countries Vaccines Market Share (%), 2015
  • Figure 7.2: BRIC Countries Vaccines Market Share (%), 2020
  • Figure 7.3: BRIC Countries Vaccines Market Share (%), 2026
  • Figure 7.4: The Chinese Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 7.5: The Indian Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 7.6: The Brazilian Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 7.7: The Russian Vaccines Revenue Forecast ($bn), 2015-2026
  • Figure 8.1: GSK Vaccines Revenue ($bn), 2012-2014
  • Figure 8.2: GSK Vaccines Region Breakdown (%), 2015
  • Figure 8.3: Merck Vaccines Revenue ($bn), 2011-2014
  • Figure 8.4: Sanofi Vaccines Revenue ($bn), 2012-2014
  • Figure 10.1: SWOT Analysis of the World Vaccines Market, 2016
  • Figure 10.2: STEP Analysis of the World Vaccines Market, 2016

Companies Listed

  • Aduro Biotech
  • Advisory Committee for Immunization Practices (ACIP)
  • Aspen
  • Astellas
  • Asterias Biotherapeutics
  • AstraZeneca
  • Bavarian Nordic
  • Baxter
  • Bayer
  • Bharat Biotech
  • Bill & Melinda Gates Foundation
  • Binnopharm
  • BiondVax
  • BravoBio
  • Brazilian Universal Health Service
  • Butantan Institute
  • Cancer Research UK
  • Center for Biologics Evaluation and Research (CBER)
  • Centers for Disease Control and Protection (CDC)
  • China National Biotec Group
  • China's National Regulatory Authority (CNRA)
  • Chinese Food and Drug Administration (CFDA)
  • Crucell
  • Developing Countries Vaccine Manufacturers Network (DCVMN)
  • Dubai Investments PJSC
  • Eli Lilly
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA)
  • Fresenius
  • GlaxoSmithKline (GSK)
  • Global Alliance for Vaccines and Immunization (GAVI)
  • Globalpharma
  • Health Service Bureau
  • Henogen
  • HIV Vaccines Trial Network
  • Immatics
  • Indian Department of Biotech
  • InnoPharma
  • Inovio Pharmaceuticals
  • International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
  • International Medica Foundation
  • InterveXion Therapeutics
  • Inviragen
  • Johnson & Johnson
  • Krka
  • LigoCyte Pharmaceuticals
  • Lupin Pharmaceutical
  • MedImmune
  • Merck & Co.
  • Ministry of Health, Labour and Welfare
  • NewLink Genetics
  • Novartis
  • Okairos
  • Pan American Health Alliance (PAHO)
  • Pfizer
  • Profectus BioSciences
  • Regulus Therapeutics
  • Roche
  • Rosteh
  • Sanofi Pasteur
  • Servizio Sanitario Nazionale (SSN)
  • Shanghai BravoBio
  • Shionogi
  • Sistema Único de Saúde (SUS)
  • Takeda
  • Themis Bioscience
  • UK National Health Service (NHS)
  • Unicef
  • US Department of Health and Human Services (HHS)
  • US National Cancer Institute
  • World Health Organization (WHO)
  • Zymeworks
Back to Top